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Abstract
Evidence shows that not only changes in skeletal muscle mass but changes in strength 
and other factors underpinning muscle quality play a role in muscle function decline and 
impaired mobility associated with aging. Changes in both strength and quality may pre-
cede loss of muscle mass. Skeletal muscle function deficit (SMFD) is a terminology that 
embraces this evolving conceptualization of sarcopenia and age-related muscle dysfunc-
tions. This chapter provides a discussion on sarcopenia in the context of SMFD, including 
operational definitions and methodological challenges associated with their establish-
ment; integration of muscle quality into SMFD; efforts to identify diagnostic cutoff values 
for low muscle mass and weakness and their predictive validity to mobility disability; 
need for standardized muscle quality assessment; clinical and public health relevance 
and research opportunities. Changes in muscle composition, based on excessive levels 
of inter- and intramuscular or intramyocellular fat are striking features increasingly 
addressed in the literature, found to affect muscle metabolism and peak force generation. 
Methods to easily and rapidly assess muscle composition in multiple clinical settings 
and with minimal patient burden are needed. Further characterization of SMFD should 
emphasize integration of muscle quality and factors behind changes in quality, as well as 
associated clinical and research implications.
Keywords: skeletal muscle function deficit, sarcopenia, reduced muscle mass, low muscle 
mass, low muscle strength, muscle quality, biomarkers, outcomes
1The views expressed in this chapter are those of the author and do not necessarily represent the views of the National 
Institute of Health, National Institute on Aging, the U.S. Department of Health and Human Services (HHS), or the U.S. 
Federal Government.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1. Introduction
Numerous efforts around the definition of sarcopenia and its better characterization through 
biomarkers including cutoff values for muscle mass, muscle strength (weakness), and per-
formance measures, as well as the identification of outcomes of clinical and investigational 
significance have evolved in the past many years and continue to be heavily investigated. 
Since 1989, when sarcopenia was first defined as an age-related reduction in muscle mass 
[1] and the association of low muscle mass and functional impairment was demonstrated 
[2], scientific and technological advances have helped us improve our understanding of the 
mechanisms underlying age-related alterations in muscle mass, muscle strength, and muscle 
quality. Substantial attention has also been given to investigate the relationships of these alter-
ations to mobility impairment, disability, fatigue, risk of metabolic disorders, falls, and mor-
tality in older adults [3]. This ongoing work responds to the need to identify preventive and 
therapeutic interventions that can delay, improve, revert, or eliminate the changes in muscle 
mass, strength, and quality. The scientific community, including regulatory scientists, and 
practicing health care professionals recognize that “a more specific definition of sarcopenia 
may not only be necessary to align it with new scientific advances, but it is highly desirable 
on practical grounds because specific criteria are critical for identifying candidate patients for 
clinical trials that test therapies aimed at reversing or alleviating the complications of sarco-
penia and its associated manifestations [4].”
It is estimated that by 2050, 2 billion people worldwide will be age ≥65 years. Preserving 
mobility and quality of life into old age will be a challenge because impaired mobility is often 
a precursor of functional decline, disability, and loss of independence. Evidence now shows 
that not only changes in muscle mass, but other factors underpinning muscle quality also play 
a role in the decline in muscle function and impaired mobility associated with aging. Changes 
in muscle quality may precede loss of muscle mass. This provides new opportunities for the 
assessment of muscle mass, strength, and quality particularly to detect who could benefit 
from interventions to prevent decline or improve muscle function [5].
The purpose of this chapter is to provide basic science, clinical researchers and expert clini-
cians with a review of the literature on key efforts to establish clinically meaningful diagnostic 
cutoff values for low muscle mass and low muscle strength, integrate muscle quality into 
these efforts, discuss the clinical and public health relevance, and highlight research oppor-
tunities for sarcopenia in the context of skeletal muscle function deficit. The new terminology 
“skeletal muscle function deficit” was coined in 2014 to embrace the evolving concepts of sar-
copenia and other aging-related muscle dysfunctions that contribute to clinically meaningful 
mobility impairments [6].
1.1. Terminology and nosology issues: sarcopenia in the context of skeletal muscle 
function deficit
Sarcopenia is a condition with a complex multifactorial etiology, which is summarized in 
Table 1 [7]. Age-related decreases in muscle performance associated with physical impairment 
are only partially explained by reduction in muscle mass, with many other  pathophysiologic 
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factors contributing to age-related impairments in muscle performance. Based on these facts, 
decreases in muscle performance and in muscle mass require independent evaluation. The 
importance of assessing muscle quality, currently defined as strength per unit of appendicu-
lar skeletal muscle mass, also continues to be highly emphasized.
Although consensus groups noted below have incorporated the criterion of impaired physi-
cal and/or muscle performance into their recommended definitions of sarcopenia, they have 
not addressed the issue of specific diagnostic terminologies. The lack of sufficient specific-
ity resulting from the use of “sarcopenia,” an anatomic term currently used to define a 
functional condition with which it is imperfectly correlated, and for which nonanatomic 
contributory factors have been identified, generates confusion. Some of this confusion 
originates from the fact that reduced muscle mass per se is a feature of several other condi-
tions in both older and younger people. Adopting a nosology that accommodates the literal 
concept of sarcopenia—reduced muscle mass—while applying other diagnostic terms for 
other age-related muscular conditions that contribute to impaired physical performance 
seems to hold a valuable clinical approach. “Skeletal muscle function deficit” (SMFD) fits 
this purpose well. The term indicates a shortfall in function that can evolve to more sig-
nificant impairment and mobility-disability. The diagnostic criteria for “SMFD” can, then, 
include: (A) Measures of muscle performance and strength that provide effective cutoff val-
ues for identifying those whose mobility disability is related to impairments. Muscle per-
formance is the capacity of a muscle or a group of muscles to generate forces to produce, 
maintain, sustain, and modify postures and movements that are required for functional 
activity. Strength is the muscle force exerted to overcome resistance under a specific set of 
circumstances. Power is the work produced per unit of time or the product of strength and 
speed. (B) Measures of muscle mass (e.g., “sarcopenic SMFD”), and (C) Measures of muscle 
quality. Factors impacting muscle quality can be described using measures of muscle com-
position or myosteatosis (fat infiltration of muscles) as these are very relevant to mobility 
outcomes and to the identification of effective preventative and therapeutic interventions in 
older adults. Muscle quality is also largely impacted by intricate intramuscular ultrastruc-
ture and morphology of contractile tissue, as well as the relationship between structure and 
function [6, 8].
A variety of known and putative muscular pathologies can be evaluated as their contribution 
to SMFD, including newly identified contributory pathologies. This approach also specifies 
other already recognized conditions that can lead to “SMFD” (e.g., diabetic polyneuropa-
thy or secondary malnutrition), which can be distinguished from age-related conditions con-
tributing to “SMFD” with etiology not yet well established. Further, it accommodates future 
knowledge in diagnostic specificity based on improved understanding of the mechanisms of 
aging and disease. Specific neurogenic factors, intrinsic muscle factors, or systemic factors 
may lead to the characterization of specific subtypes of age-related sarcopenia, to methods 
for diagnosing them, and to the identification of new therapeutic targets. In sum, the broad 
concept of “SMFD” comprising a variety of contributory etiologies provides a framework for 
developing diagnostic categories that are useful for both clinical practice and research. This 
approach has been successfully implemented with conditions that are clinically manifested as 
impaired physiologic functions (e.g., congestive heart failure, chronic obstructive pulmonary 
disease) and have multiple contributory factors [6].
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Age-related
• Reduced physical activity
• Mitochondrial dysfunction
• Anorexia of aging
• Apoptosis
• Hormones
• Low levels of testosterone
• Low levels of growth hormone
• Low levels of insulin-like growth factor (IGF)-1
• Elevated levels of cortisol
• Low levels of vitamin D
Proinflammatory cytokines
• Interleukin-1
• Interleukin-6
• Tumor necrosis factor (TNF)-alpha
• Neuronal
• Loss of motor endplates
• Peripheral neuropathy
Vascular
• Peripheral vascular disease
• Reduced capillary function
Weight loss
• Dieting
• Malabsorption
• Disease-related
Hormones
• Low levels of testosterone
• Low levels of growth hormone
• Low levels of insulin-like growth factor (IGF)-1
• Elevated levels of cortisol
• Low levels of vitamin D
Neuronal
• Loss of motor endplates
• Peripheral neuropathy
Table 1. Multifactorial etiology for sarcopenia [7].
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2. Operational definitions for sarcopenia
Several operational definitions have emphasized that sarcopenia should now be defined as 
a loss of muscle function associated with a loss of muscle mass [9–18]. This change in defini-
tion from the original meaning of sarcopenia [1] is justified by some experts as necessary due 
to current knowledge that muscle quality and muscle performance do not directly relate to 
muscle mass [19, 20]. Two very important factors are thought to be responsible for this knowl-
edge: the compromise of neuromuscular junctions in sarcopenia and the myosteatosis accom-
panying the aging process [21–24]. Below is a brief description of these operational definitions 
published by key consensus groups. It should be highlighted that a quantitative definition of 
sarcopenia that characterizes this condition in terms of rationally-defined cutoff values for 
lean body mass and muscle strength is comparable to the evolution of the operational defini-
tion of osteoporosis in terms of bone mineral density to detect individuals at increased risk for 
fractures. Efforts to identify an operational definition for sarcopenia include those:
• Based on muscle mass in relationship to the range of muscle mass within a reference 
population;
• Essentially based on expert opinion, but considering muscle mass and performance criteria;
• Essentially based on expert opinion, but considering muscle mass, muscle strength and 
physical performance; and
• Evidence-based, data-driven, considering muscle mass, muscle strength, and their predic-
tive validity to mobility disability.
Table 2 summarizes in a comparative way, the currently available operational definitions for 
sarcopenia. While they might involve similar criteria, marked variations in cutoff values exist 
as alluded below.
Working group/target 
population
Screening Operational definition
Muscle mass Muscle strength/
function
EWGSOP – European 
Working Group on 
Sarcopenia in Older People 
[9]All person ≥ 65 years
Gait speed. If gait speed is 
≤0.8 m/s, proceed to body 
composition evaluation. If gait 
speed >0.8 m/s, measure hand 
grip strength; if low muscle 
strength (weakness) is detected, 
proceed to body composition 
evaluation
Low muscle mass in 
patients with gait speed 
≤0.8 m/s or normal gait 
speed but low muscle 
strength.DXA ASM/height2 
≤7.23 kg/m2 for men; ≤5.67 
kg/m2 for women
Low grip strength <30 
kg for men; <20 kg for 
womenorgait speed 
<0.8 m/s
IWGS/IANA - International 
Working Group on 
Sarcopenia Task Force/ 
International Academy on 
Nutrition and Aging [11] 
Persons with clinical declines 
in physical function, strength, 
or health status
Physical function (4-m gait 
speed). If gait speed < 1.0 m/s, 
proceed to body composition 
evaluation
Low appendicular lean 
mass/height2 (assessed by 
DXA):≤7.23 kg/m2 for men; 
≤5.67 kg/m2 for women
Poor functioning, gait 
speed
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Working group/target 
population
Screening Operational definition
Muscle mass Muscle strength/
function
SIG- Special Interest Group: 
Cachexia-Anorexia in 
Chronic Wasting Diseases 
[12]Older persons
– Low muscle mass (≥2 
standard deviations below 
the mean measured in 
young adults of same sex 
and ethnic background)
Low usual gait speed 
(<0.8 m/s in the 4-m 
walking speed).Gait 
speed test can be 
replaced by other 
physical performance 
measures
SCWD - Sarcopenia 
with Limited Mobility 
[10]Persons >60 years with 
clinical declines in physical 
function, strength, or health 
status. Exclude specific 
muscle diseases, peripheral 
vascular disease with 
intermittent claudication, 
central and peripheral nervous 
system disorders and cachexia
Distance walked during a 6-min 
walk test (cutoff value 400 m) 
or gait speed <1.0 m/s (4- to 6-m 
track length)
Low appendicular lean 
mass/height2 (≥2 standard 
deviations below the 
mean measured in healthy 
persons aged 20–30 years 
old from the same ethnic 
group)
Poor functioning, 6-m 
walk or gait speed
AWGS -Asian Working 
Group for Sarcopenia 
[15]Community-dwelling 
persons 60 or ≥ 65 years, 
according to the definitions 
of elderly in each individual 
country.Persons with specific 
clinical conditions in all 
health care settings.
Screening in community 
settings—people aged 60 
or ≥65 years (according to 
definitions of elderly in each 
individual country) living in 
communities.Specific clinical 
conditions in all health care 
settings—presence of recent 
functional decline or functional 
impairment; unintentional 
body weight loss for over 5% in 
a month; depressive mood or 
cognitive impairment; repeated 
falls; undernutrition; chronic 
conditions (e.g., chronic heart 
failure; chronic obstructive 
pulmonary disease, diabetes 
mellitus, chronic kidney disease, 
connective tissue disease, 
tuberculosis infection, and other 
chronic wasting conditions) 
2-standard deviations 
below the mean muscle 
mass of young reference 
group or the lower 
quintile as the cutoff 
value determination.Low 
appendicular lean mass/
height2:<7.0 kg/m2 for men 
and <5.4 kg/m2 for women, 
using DXA.<7.0 kg/m2 for 
men and <5.7kg/m2 for 
women, using BIA
Gait speed ≤ 0.8 m/s 
as the cutoff value 
for low physical 
performance.Lower 
20th percentile of 
handgrip as strength 
as cutoff value for 
low muscle strength 
before outcome-based 
data are available.Low 
handgrip strength 
is suggested to be 
defined as < 26 kg for 
men and < 18 kg for 
women.
FNIH - Foundation for 
the National Institutes of 
Health, Sarcopenia Project 
[14]
Patient presents with poor 
physical function. If weakness is 
present, proceed to evaluate for 
low muscle mass; if low muscle 
mass is detected, it is possible it 
might be the cause of weakness. 
If weakness is not present or if 
low muscle mass is not detected, 
proceed to investigate for 
other causes of poor physical 
performance.
Recommended cutoff 
value:Appendicular 
lean mass adjusted to 
BMI (ALMBMI) <0.789 
for men and <0.512 for 
women.Alternate cutoff 
value:ALM <19.75 kg for 
men and <15.02 kg for 
women.
Gait speed < 0.8 m/
sRecommended cutoff 
value:Grip strength 
(GS Max) <26 kg for 
men and <16 kg for 
women.Alternate 
cutoff value:GS 
adjusted to BMI 
(GSMaxBMI) <1.0 for men and <0.56 for 
women.
Table 2. Comparative summary of sarcopenia definitions.
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Muscle mass in relationship to the range of muscle mass within a reference population. The first 
definition of sarcopenia included the relative muscle mass 2 standard deviations (SDs) below 
the mean of a large sex-specific reference population 18–40 years old [2]. This definition used 
a measure of relative muscle mass obtained by dividing absolute muscle mass estimated by 
dual energy x-ray absorptiometry (DXA) by height squared. Following, sarcopenia was clas-
sified per its severity as: (1) Class I sarcopenia (skeletal muscle index between 1 and 2 SDs 
below the young adult values) and (2) Class II sarcopenia (skeletal muscle index above 2 
SDs below the young adult reference). Skeletal muscle index was calculated by dividing total 
muscle mass by total body mass, with muscle mass evaluated by bioelectrical impedance 
analysis (BIA) [25].
Essentially expert opinion, but considering muscle mass and performance criteria. Numerous rec-
ommendations for a definition of sarcopenia consider muscle mass and performance crite-
ria. The European Working Group on Sarcopenia in Older People (EWGSOP) proposed a 
diagnosis for sarcopenia that requires low muscle mass (estimated by the ratio of appen-
dicular lean mass (ALM) over height squared, ≤7.23 kg/ht2 for men and ≤5.67 kg/ht2 for 
women) accompanied by either low muscle strength (measured by grip strength <30 kg 
for men and <20 kg for women) or low physical performance (measured by gait speed <0.8 
m/s). The group defined three stages for the condition: (1) Presarcopenia (loss of muscle 
mass); (2) sarcopenia (loss of muscle mass accompanied by either loss of strength or physi-
cal performance); and (3) severe sarcopenia, with all three aspects present [9]. The defini-
tion of sarcopenia by the International Working Group on Sarcopenia (IWGS)/International 
Academy on Nutrition and Aging (IANA) [11], the European Society for Clinical Nutrition 
and Metabolism Special Interest Group on cachexia-anorexia in chronic wasting diseases 
and nutrition in geriatrics [12], and the Society of Sarcopenia, Cachexia, and Wasting 
Disorders (SCWA) [10], require that both lean mass and gait speed be included in the diag-
nostic criteria for the condition.
Essentially expert opinion, but considering muscle mass, muscle strength, and physical performance. 
The Asian Working Group for Sarcopenia (AWGS) decided to take a similar approach for 
the diagnosis of sarcopenia, but unlike the EWGSOP, it recommends measuring both muscle 
strength (handgrip strength) and physical performance (usual gait speed) as the screening 
test [15]. The group also recommends using 60 or 65 years as the age for sarcopenia diagnosis 
per the definitions of older adults in each Asian country. The group, though, supports using 
BIA for sarcopenia diagnosis and evaluation of effects. It recommends: (A) Using 2 standard 
deviations below the mean muscle mass of young reference groups or lower quintile as the 
cutoff value determination; height-adjusted skeletal muscle mass; for using DXA, cutoff val-
ues include 7kg/m2 in men and 5.4 kg/m2 in women; for BIA, cutoff values include 7kg/m2 
in men and 5.7 kg/m2 in women, defined by appendicular skeletal muscle mass/height2. (B) 
Using the lower 20th percentile of handgrip strength of a study population before outcomes 
data are available; low handgrip strength defined as <26 kg for men and <18kg for women. (C) 
Using ≤0.8m/s as the cutoff value for low physical performance.
Evidence-based, data-driven, considering muscle mass, muscle strength, and predictive validity to 
mobility disability. The studies supported by the National Institute on Aging and the Foundation 
for the National Institutes of Health (FNIH) Sarcopenia Project utilized a data-driven analysis 
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of a large pool of data (>26,000) from studies on aging (epidemiologic and clinical trials) to 
identify criteria for clinically relevant low muscle strength (weakness) and low lean mass [17]. 
By addressing the relationship between mobility impairment (defined as gait speed ≤0.8 m/s) 
and muscle strength (measured by handgrip strength), strength cutoff values (<26 kg for men 
and <16 kg for women) were determined below where low strength (weakness) is likely to 
contribute to slow gait [26]. By relating these strength cutoff values to muscle mass (estimated 
by appendicular lean mass adjusted to body mass index [ALM/BMI]), additional cutoff values 
were determined (<0.789 for men, <0.512 for women), below which low lean mass is likely to 
contribute to low muscle strength [27]. The cutoff values resulting from these analyses were 
also found to have a predictive significance on incident mobility impairment over 3 years 
of follow-up. This two-step analyses that links a clinical condition (mobility impairment) to 
a functional test result (weakness), which is in turn linked to a potential therapeutic target 
(muscle atrophy) is useful for establishing participant selection criteria and outcome measures 
for trials of pharmaceutical or other interventions [14, 17, 28]. These studies, however, were 
conducted in relatively heathy community-dwelling older adults. In addition, harmonization 
of DXA data was not conducted prior to pooling data from all studies for analysis. Therefore, 
additional research is ongoing to validate the findings above by analysing harmonized pooled 
data from well-designed observational and interventional studies from populations of older 
adults with high prevalence of mobility disability (see RFA-AG-15-013 http://grants.nih.gov/
grants/guide/rfa-files/RFA-AG-15-013.html). The main goal is to develop and assess differing 
diagnostic cutoff values with regard to properties such as sensitivity, specificity, and positive 
predictive value. Because the populations involved display a variety of chronic conditions, 
it is possible that differing criteria might be needed to identify population subgroups. The 
extent to which lack of harmonization of DXA data significantly compromised the reliability 
of previously established cutoff values is to be seen.
2.1. Validation of the different definitions of sarcopenia
Validation of the different definitions of sarcopenia is ongoing. Using the criteria recom-
mended by the IWGS/IANA, the prevalence of sarcopenia was slightly less compared to the 
EWGSOP criteria [29]. Using the EWGSOP criteria, 4.6% of males and 7.9% of females in 
Hertfordshire were found to have sarcopenia [30]; Japanese men and women age 65–80 years 
were found to have sarcopenia at a rate of 21.8 and 22.99%, respectively [31]; among people 
80 years and older, sarcopenia was present in 12.5% [32]; and in nursing homes, 32.8% of the 
residents had sarcopenia [33]. Still using the EWGSOP criteria, sarcopenia was found to be 
highly predictive of earlier mortality in nursing home residents [34], in community-dwelling 
older Korean men [35], and in older adults admitted to acute care [36]. Sarcopenia assessed 
with the EWGSOP criteria has also been associated with a greater increase in falls [37, 38] and 
has been shown to predict mobility and instrumental activities of daily living disability [39]. 
Similarly, the SCWD criteria have been found to predict ADL and IADL difficulties, frailty 
and mortality in a longitudinal study [40].
Because the FNIH criteria were based on developing cutoffs using a variety of large epide-
miological studies [14], these criteria are more restrictive with only 1.3% of men and 2.3% of 
women being defined as having sarcopenia. While a strong negative percent agreement has 
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been reported with EWGSOP, the positive percent concurrences are generally low (5–32%). 
Additional comparative studies are needed, particularly to evaluate best predictive ability.
2.2. Methodological challenges in establishing diagnostic cutoff values
Analyses of pooled data from large studies on aging with measures of muscle mass, and 
strength still face numerous challenges including different follow-up intervals, use of more 
than one brand and/or generation of devices to measure body composition, use of more than 
one type of handgrip dynamometer, use of more than one distance to calculate gait speed, 
and data harmonization issues [17]. Cutoff values for measurements of muscle mass, muscle 
strength, and physical performance for the diagnosis of sarcopenia may also differ across 
populations due to a series of factors including race and ethnicity, body size, lifestyle, and 
cultural backgrounds. Cutoff values established for Caucasians may not be applicable to 
Africans, Asians, or Hispanics. For example, as acknowledged by the AWGS, the Asian con-
tinent has a rapidly growing population with a wide range of ethnicities, cultural, social, 
religious backgrounds, and lifestyles [15]. In addition, Asia’s aging population status and eco-
nomic development varies significantly across Asian countries. Moreover, the age cutoff that 
defines the population of older adults may differ not only among Asian countries, but also 
around the world. The lack or paucity of outcomes-based studies is another factor presenting 
a challenge to the assessment of sarcopenia.
The discussion in this section focuses on key methodological issues associated with the body 
composition assessment and the need to establish a standardized approach to develop and 
apply diagnostic cutoff values. Assessments of body composition vary in precision and in the 
target tissue. The use of anthropometric methods does not allow tissue-specific inferences. 
BMI, a descriptive index encompassing both the lean and fat mass, is expressed as weight 
divided by stature squared (kg/m2). The availability of extensive national reference data and 
their established relationships with levels of body fat, morbidity, and mortality in adults is an 
advantage to the use of BMI. However, the use of BMI alone to evaluate athletes and persons 
with conditions such as sarcopenia where body weight may be altered considerably by chang-
ing proportions of muscle and fat masses is cautioned [41].
BIA produces estimates of total body water, fat-free mass, and fat mass by measuring the 
resistance of the body as a conductor to a very small alternating electrical current. This is not 
a direct measure of skeletal muscle. Measurements can be easily altered by fluid retention and 
health status, providing inaccurate results that limit considerably the clinical application. BIA 
was developed to mainly determine the volume of body fat and muscle mass, but not specific 
appendicular muscle mass. While validation studies have been reported on BIA’s accuracy in 
the diagnosis of sarcopenia, results also strongly depend on the accuracy of the equation of 
the equipment and the conditions associated with the assessment (e.g., temperature, humid-
ity, skin condition, and others) [42–45]. New BIA equipment models will likely provide more 
precise measurements of appendicular muscle mass [24, 46]. Portability, reasonable cost, fast 
processing, noninvasiveness, radiation-free functions, and convenience of use are advantages 
to BIA suitability for sarcopenia assessment in the community. Despite recommendations 
by EWGSOP on the use of BIA validated equations in sarcopenia research, its use has been 
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discouraged by others [10, 47]. Moreover, BIA equipment in Western countries is not derived 
from populations from other regions of the world and, therefore, results are unlikely to be 
able to be extrapolated to particular populations [15].
Currently, the precision of devices to measure body composition such as DXA, computed 
tomography (CT), and magnetic resonance imaging (MRI) has been well recognized [47]. 
DXA is currently the most widely employed method for muscle mass measurement in 
sarcopenia research. It is commonly available in both clinical and research settings, is rela-
tively inexpensive, and provides sufficiently precise results [41, 47, 48]. DXA is considered 
a suitable alternative to distinguish between fat, bone mineral, and lean tissues, it leads to 
minimal radiation exposure. However, its use in community screening is still challenging. 
In 2008, the Center for Disease Control and Prevention (CDC), National Center for Health 
Statistics (NCHS) released a DXA whole body dataset from the National Health and Nutrition 
Examination Survey (NHANES) population-based sample acquired with modern fan bean 
scanners in 15 counties across the United States from 1999 through 2004 [49]. The reference 
dataset was partitioned by gender and ethnicity and DXA whole body measures of %fat, fat 
mass/height2, lean mass/height2, appendicular lean mass/height2, %fat trunk/%fat legs ratio, 
trunk/limb fat mass ratio of fat, bone mineral content (BMC), and bone mineral density (BMD) 
were analysed to provide reference values for subjects 8–85 years old. DXA reference values 
for adults were normalized to age; reference values for children included total and subtotal 
whole body results and were normalized to age, height, or lean mass.
The estimation of fat and lean tissue by DXA is based on assumptions regarding levels of 
hydration, potassium content, or tissue density, and these assumptions vary with manufac-
turer. Some analytical differences across manufacturers and models, and the risk of generat-
ing biased results due to the low differentiation between water and bone-free lean tissue are 
among limitations with DXA [48]. Estimates of body composition are also affected by differ-
ences in software employed, methodological issues, and intra- and intermachine differences. 
Testing of specific manufacturers and models revealed that overestimations of fat-free mass 
may occur. DXA systems are currently capable of scanning a very broad range of weights 
(neonates to morbidly obese). Repeatability is also very high for all reported total body mea-
sures, with the percent fat measures typically better than 1% (standard deviation) and 2% 
(coefficient of variation) for total fat and lean mass measures. Whole-body DXA scans can 
be subdivided into arms, legs, trunk, head, and android/gynoid soft tissue regions to report 
all bone and soft tissue measures within a region. While work is ongoing, there is not yet a 
reliable phantom that can be used to cross-calibrate DXA systems between manufacturers or 
a standard of accuracy of percent fat. Some success at representing muscle mass as appen-
dicular lean mass in just the legs and arms has been achieved, but it has yet to be shown as a 
reasonable surrogate of muscle strength or function. Further work with DXA machines will 
lead to the development of more refined models of visceral and muscle fat [47].
Despite being considered gold standards for the evaluation of body composition, the use of 
computed tomography (CT) and magnetic resonance imaging/spectroscopy (MRI)/(MRS) has 
been impacted by their high cost, CT-generated radiation exposure, and inconvenience for 
use in community screening. Both are techniques relevant to body composition assessment 
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requiring additional time and software to provide whole body quantities of fat and lean tis-
sue. CT can distinguish body tissues based on a technique helpful to assess nonfat tissue or 
the fatty infiltration of skeletal muscles. It accurately measures a direct physical property of 
the muscle (e.g., cross-sectional area and volume). It allows the evaluation of muscle density 
(a parameter related to intramyocellular adipose tissue deposit) as well as subcutaneous and 
intramuscular adipose tissue deposition [48].
MRI/MRS has been increasingly used to study body composition in related physiological and 
pathological conditions. MRI can be used for whole body assessment in normal or moder-
ately overweight people (limitations exist in accommodating very obese people) and measure 
the volume of body components (e.g., fat tissue, skeletal muscle, organs, and bone). Recent 
advances suggest that fat tissue is not a homogeneous depot but contains distinct components 
with different metabolic activities. MRI provides similar measures as CT, with the additional 
capacity of multiple slice acquisition and 3D volumetric estimates, and no radiation expo-
sure. Quantification of subregions of fat depots such as visceral (i.e., omental, mesenteric, and 
extraperitoneal), intermuscular, and bone marrow is possible with DXA. A single slice in the 
upper abdomen has been shown not only to provide the best representation of total volume 
of visceral fat, but also to correlate with health risks even more closely than the traditionally 
used slice located at the L4–L5 level. When fat infiltration is increased, MRS imaging allows 
a more accurate measurement of intramyocellular fat [41, 47]. High technical complexity and 
costs, as well as inapplicability to persons with older models of implanted medical devices 
(e.g., joint prostheses) are among the limitations associated with MRI.
2.2.1. Harmonization of DXA data from multiple studies
Studies focusing on the development of cutoff values for low muscle mass and low muscle 
strength frequently use appendicular lean mass (ALM) as a primary independent variable, 
obtained by DXA. Because these studies generally combine data from many different cohorts 
to measure ALM, it is critical that DXA measurements be compatible across studies. Owing 
to the variation between the manufacturers’ (Hologic and GE Lunar) designs and systematic 
improvements in hardware and software instituted over time within each machine type, DXA 
values obtained for a given individual may vary across machines. It is necessary, therefore, 
to implement a quantitative adjustment to harmonize or put all measurements on the same 
theoretical scaling. This harmonization process may require a few steps including the harmo-
nization of DXA values within manufacturer’s systems and harmonization between different 
manufacturers. Studies have been conducted to address standardization and cross-calibration 
of body composition using GE Healthcare Lunar and Hologic DXA systems. Equations devel-
oped are facilitating the combination of results in clinical and epidemiological studies [50–52].
2.3. Sarcopenia diagnosed without measurements
Fracture risk can be determined almost accurately by FRAX questions as by measuring bone 
mineral density [53]. Because muscle function is more noticeable than bone function, the idea 
of developing and adopting a simple questionnaire to identify individuals with sarcopenia 
was realized with the development of the SARC-F scale. This simple and rapid questionnaire 
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to assess the presence of sarcopenia is illustrated in Table 3 [54]. Robust validation, indicating 
that SARC-F performed at similar level to the EWSGSOP and AWGS definitions of sarcopenia 
has been reported, with suggestions that sarcopenia can be screened for without a need to 
measure muscle mass or to directly measure muscle function [55].
2.4. Sarcopenia and the FY2017 United States Update of the International Statistical 
Classification of Diseases and Related Health Problems, 10th Revision, Clinical 
Modifications (ICD-10-CM)
Effective October 1, 2016, the U.S. Department of Health and Human Services (HHS) Centers 
for Disease Control and Prevention (CDC) has established an ICD-10-CM code for “sarcope-
nia” (M62.84) for use by the medical community in the United States [56]. For that purpose, 
sarcopenia is defined as a combination of low muscle mass and weakness in older adults that 
leads to functional deficits. The new code designation for the condition has the potential to 
affect the clinical assessment and management of sarcopenia, as well as facilitate data col-
lection and impact sarcopenia research. Because sarcopenia is a condition that can lead to 
serious adverse outcomes (e.g., mobility impairment, falls, disability, and death) [25, 57–61], 
the creation of an ICD10-CM code emphasizes the importance of recognizing and treating the 
condition. The availability of an ICD-10-CM code for sarcopenia has the potential to facilitate 
recognition of the condition and the future establishment of guidelines for the clinical diagno-
sis and management of sarcopenia; support requests for tests and referrals, and the develop-
ment of educational materials targeting potential prevention and management of sarcopenia. 
It can serve as a stimulus to advance research including new drug development and new 
indications by the HHS Food and Drug Administration (FDA) for the treatment of sarcopenia. 
It can certainly contribute to easier access to more reliable data collection on the condition by 
a variety of system data sources (e.g., electronic medical records, death certificates). Despite 
these potential advantages, challenges are faced with the need to increase awareness of the 
availability of such code and, most importantly, how to use it in face of the current lack of a 
standardized clinical/diagnostic assessment of sarcopenia.
Evaluation component Questions Scoring
Strength How much difficulty do you have in 
lifting and carrying 10 pounds?
None = 0Some = 1A lot or unable = 2
Assistance with walking How much difficulty do you have 
walking across a room?
None = 0Some = 1A lot, use aids, or 
unable = 2
Rising from a chair How much difficulty do you have 
transferring from a chair or bed?
None = 0Some = 1A lot or unable 
without help = 2
Climbing stairs How much difficulty do you have 
climbing a flight of 10 stairs?
None = 0Some = 1A lot or unable = 2
Falls How many times have you fallen in 
the past year?
None = 01 to 3 falls = 14 or more 
falls = 2
Table 3. SARC-F scale: scores of 4 or more indicate sarcopenia [54].
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2.5. Biomarkers and outcomes for sarcopenia
The most basic biomarkers (functional, biological, or imaging-related) that can be utilized 
in clinical trials of sarcopenia and considered the most reliable and promising to evaluate 
age-related changes of skeletal muscle have been discussed and recommended. Table 4 sum-
marizes information on these proposed biomarkers for sarcopenia research. In addition, the 
measurement of motor unit number index, which can be used to assess the number and the 
size of the motor units is a very important biomarker as loss of motor unit input to muscle is 
a significant cause of sarcopenia in at least half of older individuals [22, 48, 62].
In view of the molecular mechanisms involved in the pathogenesis of sarcopenia, potential 
emerging sarcopenia biomarkers have been discussed. Normal muscle mass and function 
maintenance are thought to be dependent on the dynamic balance between the positive regu-
lators of muscle growth such as bone morphogenetic proteins (BMPs), brain-derived neuro-
trophic factor (BDNF), follistatin (FST) and irisin, and negative regulators including TGFβ, 
myostatin, activins A and B, and growth and differentiation factor-15 (GDF-15). The authors 
hypothesized that the shift in this balance to muscle growth inhibitors, along with increased 
expression of the C-terminal agrin fragment (CAF) associated with age-dependent neuromus-
cular junction (NMJ) dysfunction, as well as skeletal muscle-specific troponin T (sTnT), a key 
component of contractile structure, is a main mechanism underlying sarcopenia pathogen-
esis. Based on these facts, the molecular elements mentioned above are proposed as emerging 
sarcopenia biomarkers [63].
As indicated previously the EWGSOP recommends the use of physical performance, muscle 
strength, and muscle mass as the primary treatment outcome indicators for sarcopenia inter-
vention trials. Activities of daily living, quality of life, metabolic and biochemical markers, 
inflammatory markers, global impression of change by subject or physician, falls, admission 
to nursing home or hospital, social support, and mortality are recommended by that group as 
secondary outcome indicators [9].
The AWGS recommends the following approach in outcome indicators assessment for sarco-
penia research. This approach targets the measurement of changes in two ways over a period. 
The AWGS also recommends the use of fear of falling and incontinence as outcome indicators 
for sarcopenia research [15]:
a. Static approach: Activities of daily living, quality of life, inflammatory markers, falls, frail-
ty issues, mobility disorders, admission to hospitals, admission to long-term care facilities, 
and mortality.
b. Dynamic approach: Changes in muscle mass, muscle strength, physical performance, frail-
ty status, instrumental activities of daily living, and activities of daily living.
Finally, the importance of tapping into the patient experience, identifying the linkage between 
clinical measures and patient reports, and building self-report into submissions for drug 
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Inclusion-exclusion criteria Baseline evaluation Endpoint assessment
Muscle function Physical performance measures
Muscle strength measures
Disability
+++
+++
+++
+++
+++
+++
+++
+++
+++
Muscle mass Anthropometry
Bioelectrical impedance analysis
Dual energy X-ray absorptiometry
Computerized tomography
Magnetic resonance imaging
Echography
Electrical impedance myography
+
+
+++
++
++
++
+
-
-
++
+++
+++
++
++
-
-
++
+++
+++
++
++
Biological confounders 
(mechanisms)
Note:
The importance of all these 
biomarkers in the evaluation 
of sarcopenia will largely 
depend on the study 
hypotheses, the specific aims, 
and/or the target population
Inflammation
Oxidative damage
Antioxidants
Apoptosis
Nutritional parameters (albumin, 
hemoglobin, urinary creatinine, 
others)
Hormones 
(dehydroepiandrosterone, 
testosterone, insulin-like growth 
factor-1, others)
++
++
++
+
+++
 
 
++
++
++
++
++
++
 
 
++
++
++
++
++
++
 
 
++
- not recommended for this use; + may be of use; but severely limited; ++ suitable for this use; +++ recommended for this use.
Table 4. Potential biomarkers for clinical trials on sarcopenia [48].
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approval to the HHS FDA have been a matter of discussion among experts. Work is ongo-
ing with questionnaires focusing on patient-reported outcome measures in sarcopenia, but 
validation is pending [64]. In addition, the HHS FDA conducted on April 06, 2017, a public 
meeting on patient-focused drug development for sarcopenia. The HHS FDA is interested in 
obtaining patient perspectives on the impact of sarcopenia on daily life and patient views on 
treatment approaches.
3. Integrating muscle quality in efforts to define sarcopenia and muscle 
quality in the context of skeletal muscle function deficit
Aging is associated with significant changes in body composition, gradual increase in total 
body fat during adulthood followed by a loss later in life, and remodeling of fat distribution. 
The latter involves an increase in inter/intramuscular and visceral fat, and a gradual loss of 
subcutaneous fat. Weight gain and weight loss overtime have been linked with preserved 
muscle mass and accelerated muscle atrophy, respectively. Both, however, are associated 
with increased fat infiltration of muscles. Adverse health and functional outcomes including 
the development of insulin resistance and impaired mechanical muscle function seem to be 
concurrently or independently associated with the aging changes mentioned above. Evidence 
suggests that the correlation between “muscle quantity” and “muscle function” (e.g., muscle 
strength) is relatively weak, and in contrast to muscle strength, muscle mass has been dem-
onstrated to be a poor predictor of functional limitation, gait speed, and even mortality. It is, 
in fact, becoming increasingly clear that muscle quality (force per unit of muscle mass) and 
neural function play a key role in the development of mobility disability and that a new end-
point incorporating these aspects in addition to muscle mass and strength might be useful.
3.1. Defining muscle quality: the need for a standardized assessment
Multiple factors are known to underpin muscle quality and determine the changes in muscle 
function and mobility later in life. Those who conduct sarcopenia-related research have usu-
ally used relative force production (ratio of peak force and a measure of body size, regional 
lean body mass, or cross-sectional area) as the favored approach to characterizing muscle 
quality [65, 66]. Emerging definitions of muscle quality, however, call for its expansion to 
include muscle composition, metabolism, aerobic capacity, insulin resistance, fat infiltration, 
fibrosis, and neural activation [67], all of which easily correlate with the concept of SMFD. The 
term muscle quality allows investigators to explore aspects of SMFD beyond the construct of 
age-related decline of lean body mass [6]. While the meaning of muscle quality is linked to the 
primary functions of the skeletal muscle, it can be expanded to include both physiology and 
pathophysiology [8]. There is also a need to develop and adopt a standardized assessment of 
muscle quality. In doing so, it is essential to consider the complexity of the skeletal muscle 
tissue and its physiologic roles that include not only movement via force production, but 
also metabolism through its maintenance of glucose/insulin homeostasis and amino acid stor-
age, thermoregulation, and autocrine/paracrine/endocrine signaling via myokine production. 
This expanded view of muscle quality is essential to improve our understanding of SMFD [8].
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A preliminary conceptual model for the assessment of muscle quality has been proposed, 
built on skeletal muscle primary physiologic functions. This conceptual model is categorized 
in domains that have both clinical and research applications. The domains are the following: 
(A) force production; (B) metabolism (endocrine, neurologic, orthopedic); (C) thermoregula-
tion; and (D) signalling/myokine production. No endpoint(s) have been identified as best to 
establish the quantitative profile of muscle quality. Similarly, no standardized approaches 
to endpoint measures have been recommended that can be linked to any of the domains 
above. None have been identified as the most strongly associated with mechanisms control-
ling muscle function or with predicting mobility status and mortality in older adults. Muscle 
quality seen under this perspective provides the advantage of going beyond the strict lean 
body mass-driven assessment approach to sarcopenia research. Ongoing research focusing 
on the local and systemic effects of fat infiltration of muscles and on the emerging methods to 
quantify changes in muscle composition and function is reflecting this perspective [8].
3.2. Factors underpinning muscle quality
Below is a brief discussion on the multiple factors underpinning muscle quality, all of which 
fall under the proposed domains for assessing muscle quality. The concept of muscle quality 
cannot be represented by a single endpoint measure, but the factors that affect muscle quality 
are frequent targets of measurement used to characterize skeletal muscle. The discussion pro-
vided in this section does not enclose every assessment target, but addresses common exam-
ples of factors that may serve as measures for basic, translational, and clinical trials related to 
muscle quality and sarcopenia or muscle quality in the context of SMFD. Factors intrinsic to 
skeletal muscles are crucial for function and homeostasis. Factors extrinsic to skeletal muscles 
considerably impact muscle activity and muscle mass building and maintenance. Both intrin-
sic and extrinsic factors affect net force production.
3.2.1. Muscle characteristics/architecture
Muscle characteristics include size, fiber type, and contractile components. Fiber type and 
number determine muscle size. Muscle cross-sectional area has a positive relationship with 
muscle strength in young lean individuals, while smaller and weaker muscles are usually seen 
in older adults. Muscle cross-sectional area and lower limb skeletal muscle volume are asso-
ciated with greater fat mass in both men and women [68], likely due to intermuscular lipid 
or noncontractile components. There are three types of muscle fibers as identified in Table 5 
[68]. The loss of types I and IIb muscle fibers associated with aging is attributed to changes in 
activity and consequent disuse and denervation. Conflicting literature demonstrates no link 
at all or a link between advanced age and changes in muscle fiber composition with gradual 
loss of type IIb muscle fibers [69]. Conflicting limited evidence is also seen in older adults in 
relation to changes in muscle fiber type, muscle cross-sectional area, and strength. Contractile 
properties of types I and II muscle fibers at the single fiber level seem to be maintained inde-
pendent of the presence of mobility limitation [70], but again, evidence is conflicting. It has 
been suggested that maximal shortening velocity is lower in single fibers from older adults 
because of changes in myosin heavy chain isoform distribution to a more hybrid pattern. A 
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lower maximal shortening velocity in myosin heavy chain has been observed in types I and 
IIa fiber of older adults including those who are very active. The evidence, however, is debat-
able because of limitations with study power and potential confounding with physical activ-
ity. Preservation of single muscle fiber contractile properties with age is thought to imply that 
differences in skeletal muscle function are related to quantitative changes in muscle fiber size 
or number rather than qualitative changes in the muscle’s contractile properties [68].
Fiber arrangement within a muscle (e.g., parallel or pennation pattern) will determine fascicle 
length, pennation angle, and cross-sectional area, all of which can change with age. Older 
adults 70–81 years of age are reported to have smaller fascicle length and pennation angle 
(compared to younger adults 27–42 years) of the gastrocnemius medialis [71], but several 
weeks of bed rest have not resulted in changes in the pennation angle of the vastus lateralis 
muscle. Nevertheless, modest improvements in muscle architecture are reported to be pos-
sible with 4–5 weeks of resistance training. Changes in muscle architecture also appear to 
precede changes in muscle size in young healthy adults.
Cross-sectional assessment of skeletal muscles provides relevant information on muscle func-
tion because both individual muscle fiber diameter and cross-sectional diameter of the whole 
muscle are associated with strength. Force production is related to the architectural char-
acteristics of the skeletal muscle including muscle fiber length and arrangement in relation 
to the direction of the force produced by the whole muscle. Thus, both cross-sectional and 
longitudinal orientation of measures of skeletal muscles are valuable in the assessment of the 
size-strength relationship and the identification of age-related differences in muscle strength 
per size. Sarcomeric changes in myofibrillar disorder, Z-line streaming, and dilatation in aged 
skeletal muscle have been observed in electron microscopic analysis. The characteristics/
architectural changes highlighted above have been combined in a composite measure—phys-
iological cross-sectional area (PCSA)—to reflect both strength and change in strength in leg 
extension [8].
Muscle weakness is attributed to changes in muscle composition, muscle contractile quality, and 
neural activation [72]. However, measures of muscle composition, size, and architecture gener-
ally do not consider the neural input into fibers, which dictate contraction potential and force 
production. Strength measures are an important indicator of muscle performance and show 
the ability to change in response to a variety of interventions to tackle sarcopenia and frailty 
Type I Type IIa Type IIb
Predominantly generate energy via 
oxidative pathways for prolonged 
low force production.Relatively 
small cross-sectional area compared 
to type IIb fibers, but have greater 
oxidative capacity.Recruited during 
low intensity activities of daily living 
(e.g., walking)
Capable of generating energy via 
oxidative and nonoxidative pathways
Predominantly generate energy via 
nonoxidative pathways for rapid 
high force production.Recruited 
during high intensity activity
Table 5. Types and functions of skeletal muscle fibers [68].
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in older women with clinically relevant muscle weakness independent of the presence of low 
muscle mass [73]. Muscle strength and size have been used as a single measure of muscle qual-
ity known as “relative strength,” reflecting the expression of muscle force production relative 
to muscle or body size. It has been suggested that strength per unit of muscle tissue may serve 
as a better indicator of age-related differences in muscle quality prior to changes in lean tissue 
mass [74]. A novel functional metric─muscle quality index─estimates muscle power from body 
anthropometrics and timed chair raises; it has been found to have higher reliability and greater 
responsiveness following a resistance exercise regimen in older adults, compared to other func-
tional measures (e.g., gait speed, grip strength, the get-up and go test, etc.) [75].
3.2.2. Muscle aerobic capacity
Muscle quality and function in both middle-aged and older adults are determined by meta-
bolic characteristics of the muscle. Aerobic capacity reflects the maximal ability to use oxygen 
(cardiovascular adaptation to transport oxygen; within skeletal muscle adaptation to use oxy-
gen) in response to energy demands of physical activity. Evidence shows that aerobic capac-
ity declines at an accelerated rate after age 50, and is a strong predictor of mobility assessed by 
gait speed in older adults. Evidence from cross-sectional muscle analyses from healthy men 
and women (18–90 years) reveals that mitochondrial DNA, mRNA abundance, and energy 
(ATP) production diminishes with age. Both skeletal muscle mitochondrial capacity and effi-
ciency, and whole body peak aerobic capacity have been linked to gait speed [68, 76, 77].
The progressive decline in mitochondrial function observed in aging results in the accumula-
tion of reactive oxygen species (ROS) generated by the incorporation of a single electron to the 
oxygen molecule. Specifically, ROS negatively impact muscle quality, playing an extremely 
important role in all muscle functions, muscle aging, contraction, fatigue, dystrophy or waste 
[78–80]. Mitochondria are the major producers of ROS, which damage DNA, proteins, and 
lipids. Animal and human studies have typically shown that aging changes in mitochondria 
can be reflected by increased mutations in mitochondrial DNA, decreased activity of some 
mitochondrial enzymes, altered respiration with reduced maximal capacity at least in sed-
entary individuals, and reduced total mitochondrial content with increased morphological 
changes. With mitochondrial dynamics altered (e.g., fusion and fission rates, mitochondrially 
induced apoptosis), net muscle fiber loss and age-related sarcopenia may ensue. Strategies 
such as exercise and caloric restriction that reduce oxidative damage can improve mitochon-
drial function. While these strategies may not completely prevent the primary effects of aging, 
they may help to attenuate the rate of decline [81, 82].
It is also well established that contracting muscles produce both ROS and nitrogen species. 
Although the sources of oxidant production during exercise continue to be debated, grow-
ing evidence suggests that mitochondria are not the dominant source [83]. Regardless of the 
sources of oxidants in contracting muscles, intense and prolonged exercise can result in oxida-
tive damage to both proteins and lipids in the contracting myocytes. Further, oxidants regu-
late numerous cell signaling pathways and modulate the expression of many genes. There 
has been much controversy about measurements of mitochondrial energy production. These 
controversies may be explained by differences in methodological approaches and whether 
physical activity is controlled for.
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Age-related changes in skeletal muscle mass and composition can result in increased insu-
lin resistance and later to reduced capacity for insulin-mediated glucose disposal. Relative 
muscle mass in healthy nondiabetic older adults is inversely linked to glucose tolerance and 
insulin resistance [84]. Muscle strength adjusted for BMI, however, has been reported to 
be negatively associated with insulin resistance in a large population based study of older 
women, but not men, after adjustment for confounders. No association between muscle leg 
strength and insulin resistance in men or women >50 years has been observed in an analysis 
of the National Health and Nutrition Examination Survey (NHANES) [85]. In some studies, 
gait speed assessments are found to be inversely associated with insulin resistance, suggest-
ing that insulin resistance may serve as an indicator of poor muscle quality underpinning low 
levels of physical fitness and poor scores on gait speed tests. Improvement in glucose disposal 
and skeletal muscle metabolism in older overweight or obese men has been observed over 6 
months of both regular aerobic and resistance exercise. Fat infiltration of muscles is also asso-
ciated with insulin resistance.
3.2.3. Myosteatosis
Myosteatosis refers to fat infiltration in skeletal muscle that can lead to large negative clinical 
effects including poor metabolic and skeletal muscle health, accelerated aging, and impaired 
longevity. This ectopic fat tissue has become an important factor behind muscle quality and 
may serve as a predictor of muscle function in older adults. Two modalities of myosteatosis 
are identified: (1) intermuscular fat, which represents the visible extracellular adipose tissue 
located beneath the muscle and between and within muscle groups; (2) intramuscular fat 
or intramyocellular lipids, which represents infiltration within myocytes, i.e., the presence 
of microscopic lipid droplets used as energy within the muscle. This ectopic fat infiltration 
increases with aging, seems to act synergistically with sarcopenia and is also present in mus-
cular dystrophies. The biological mechanism underlying increases in myosteatosis with aging 
in humans remain largely under investigated, with the need to identify and better understand 
regulatory factors including evidence of senescent cells and cultured cells developing into 
preadipocytes and fat cells. This is an opportunity for future development of therapies to 
preserve skeletal muscle health [8, 86, 87].
Individuals with comparable thigh circumference may have distinct muscle function due to 
the proportion of fat infiltration to contractile elements. In older adults with multimorbidity, 
intermuscular adipose tissue evaluated by MRI was reported as the strongest predictor of 
mobility, but strength and quadriceps lean tissue explicated some of the variation in mobility 
in this study [88]. Increased mobility loss, reflected by decreased six-minute walk distance, 
decreased gait speed, decreased physical performance, difficulty with repeated chair stands, 
and slower stair descent and timed get-up and go tests have been reported as the result of 
myosteatosis effects on muscle metabolism and function [8]. In young healthy persons with 
30 days of leg disuse by suspension, myosteatosis was found to increase by 15–20% and 
exceeded the loss of lean muscles (calf and thigh) [89]. Myosteatosis is also known to lead to 
the transition of muscle fibers from type II to type I, which result in muscles with impaired 
contractile capacity and decreased power [90, 91]. It is also suggested that myostetatosis may 
harm muscle and mobility because fat infiltration leads to changes in muscle fiber orientation. 
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Proinflammatory cytokines secreted by fat tissue in the skeletal muscle microenvironment 
may also lead to proteolysis and muscle catabolism [8].
Fat storage and infiltration into muscle may be a marker of metabolic profile. In older adults, 
intermuscular adipose tissue was found to positively correlate with higher fasting plasma glu-
cose and lower glucose tolerance [92]. Myosteatosis has been linked to insulin resistance and 
an increased risk of developing type-2 diabetes, hypertension, and dyslipidemia, independent 
of total body adiposity (measured by BMI or DXA whole body fat). Further investigation, 
however is still needed on the association of myosteatosis and metabolic disease independent 
of visceral fat. The metabolic consequences of myosteatosis depend on age, race/ethnicity, 
aerobic conditioning, sensitivity to insulin, amount of physical activity, and anatomic region. 
Further investigations are necessary to verify whether myosteatosis acts as a marker of meta-
bolic dysfunction or may have an intermediary modifying role in insulin resistance [8].
Physical activity seems to be able to revert intermuscular fat infiltration. In men 60 years old, 
six months of aerobic exercise and weight loss decreased intermuscular adipose tissue of the 
leg and improved fasting plasma glucose and glucose tolerance. Four weeks of an imposed 
decrease in physical activity due to unilateral lower limb suspension resulted in 15–20% 
increase in the intermuscular adipose tissue in the thigh and calf, respectively. Strength loss 
was associated with the increase in the intermuscular adipose tissue, after adjustment for loss 
of muscle mass and considering initial baseline values.
3.2.4. Muscle fibrosis
Impairment in the muscle repair process can lead to muscle fibrosis, which involves the depo-
sition of collagen and extracellular matrix proteins instead of proteins necessary to repair and 
restore tissue function. Fibrosis is also seen in different tissues because of extra fat accumula-
tion. The presence of fibrosis in the skeletal muscle of older adults is hypothetical at this point, 
and further studies are needed to investigate how or whether fibrosis is a factor in muscle 
quality. Evidence, however, is available indicating that progressive intermuscular adipose tis-
sue infiltration in middle aged or older adults may lead to fibrosis and impairment of muscle 
function and mobility [68].
3.2.5. Motor units and neuromuscular activation
Other potential factors related to muscle quality in middle and old age include components 
of the neuromuscular system and neuromuscular activation. Skeletal muscle fibers are orga-
nized in bundles of motor units. Each motor unit is innervated by a motor nerve, which con-
nects to an alpha motor-neuron in the spinal cord. Across the lifespan, motor units go through 
remodeling, denervation and reinnervation. These units are reported to be decreased in the 
tibialis anterior muscle of men 65 years old and those >80 years compared to younger men (25 
years), but the reduced motor unit number was only related to strength in men >80 years [93].
Neuromuscular activation has been proposed as another measure of muscle quality. Impairments 
in neuromuscular activation affect the rate of force development and muscle power needed for 
dynamic movements. Improvements in neuromuscular activation generally precede increases 
in muscle mass in response to resistance training. Neuromuscular activity and acceleration was 
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impaired during dynamic leg extensions in mobility-limited older adults compared to mobile 
older adults [94]. The rate of neuromuscular activation was significantly associated with physi-
cal function scores. Among middle-aged and older adults without mobility limitations, no sig-
nificant differences in measures of neuromuscular activation were detected. However, whether 
neuromuscular impairment precedes the development of mobility limitations is still unclear.
3.3. Emerging alternative clinical imaging and other measures of muscle quality
Relatively high costs, limitations with access, and the testing burden associated with inva-
sive techniques are barriers to standardized assessment of muscle quality. The use of rou-
tine tissue composition analysis is hampered by the need for further demonstration of its 
diagnostic value and contribution to both diagnostic and therapeutic decision making. The 
emerging literature on the effects of age-related increases in intramuscular adipose tissue on 
muscle performance and metabolism, has led to the development of alternative assessment. 
Methodological approaches ranging from multifrequency electrical impedance analysis to 
quantitative diagnostic sonography have been used to characterize skeletal muscle mass and 
quality in older adults and in those with muscle disease [95]. Noninvasive, high precision, 
imaging modalities such as MRI has been used to diagnose and assess progression of a num-
ber of neuromuscular conditions. Quantitative musculoskeletal diagnostic ultrasound has 
been proposed as a clinically feasible means of characterizing muscle structure. Ultrasound 
has been shown to be highly reliable for assessing cross-sectional areas of large individual 
human muscle and particularly useful in mobility-impaired individuals who cannot be easily 
transported to scanners (CT, MRI) [48].
Electrical impedance myography (EIM) is another promising technique based on the surface 
application and measurement of a high frequency, low intensity electrical current applied to 
specific muscles. It detects changes in the conductivity and permittivity of skeletal muscles 
caused by alterations in muscle composition and structure. It has been found repeatable and 
sensitive to skeletal muscle changes in persons with amyotrophic lateral sclerosis. Mass iso-
potomer distribution analysis based on the evaluation of protein and proteome synthesis rate 
is obtained by heavy water labelling; it is a very promising approach due to the wide spec-
trum of proteins analysed [48].
The success of emerging alternative imaging measures of muscle quality relies on their easy-
to-use in diverse clinical settings and ability to discriminate between older adults with and 
without sarcopenia, identify those at risk for impaired muscle performance, and those who 
can benefit from preventive and therapeutic interventions. A symposium report on “The 
Need for Standardized Assessment of Muscle Quality in Skeletal Muscle Function Deficit 
and Other Aging-Related Muscle Dysfunctions” provides a good insight on these emerging 
approaches [8].
4. Conclusion: clinical relevance and research opportunities
Aging muscles and other aging-related muscle dysfunctions present with a functional deficit 
in one or more elements or components of SMFD involving muscle mass, muscle strength 
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or muscle quality. To further characterize SMFD, additional investigation and understand-
ing of the factors behind changes in muscle quality with aging are needed. The concept of 
muscle quality is critical and should be expanded beyond muscle strength or power per unit 
of muscle mass, to encompass muscle aerobic capacity and other key factors which closely 
relate to mobility and other important activities of daily living. Assessment or diagnostics 
tools sensitive to small changes within skeletal muscle that precede a decline in mass, strength 
and function can enable preventative steps to maintain healthy muscles. Diagnostic ultra-
sound and other assessment methods continue to be developed for characterizing muscle 
pathology, and enhanced sonography using sensors to provide user feedback and improve 
reliability is currently the subject of ongoing investigation and development. Measures of 
relative muscle force (e.g., specific force or grip strength adjusted for body size) have been 
proposed as methods to assess changes in muscle quality. Performance-based assessments of 
muscle power via timed tests of function and body size estimates are associated with lower 
extremity muscle strength and may be responsive to age-related changes in muscle quality. 
The challenge remains to reach a consensus on diagnostic criteria, tools, and consistent meth-
odological approaches for assessing or measuring components of SMFD that are practical in 
a community or clinical setting. These should be considered priority for the scientific com-
munity and health care providers.
To date, no studies have assessed exclusively and concurrently aging-related changes in 
muscle mass, muscle strength, muscle function, and muscle quality. Analyses of pooled data 
from large studies on aging with measures of muscle mass and strength still face numer-
ous methodological challenges. As highlighted by experts in the field, future well-designed 
large prospective studies of interventions to improve muscle mass, muscle strength, muscle 
function, and muscle quality can observe age-related changes in skeletal muscles over time 
and generate the evidence to help identify individuals that will benefit from interventions to 
prevent or treat these changes.
From the public health perspective, further characterization of SMFD is very relevant to sev-
eral ongoing therapeutic developments. For example, we already know that resistance exer-
cise is the primary therapeutic strategy to prevent and reverse sarcopenia; aerobic exercise 
also has a therapeutic role, as demonstrated by the Lifestyle Interventions and Independence 
for Elders (LIFE); vitamin D has been shown to enhance muscle function in persons with 
low muscle function; and evidence that leucine-enriched essential amino acid supplementa-
tion will increase muscle mass and potentially function. Limited evidence, however, suggests 
that testosterone increases muscle mass and strength, and potentially function in older adults 
with hypogonadism, but its safety remains unclear. Drug development efforts with selective 
androgen receptor modulators (SARMs) are promising in increasing muscle mass and stair 
climbing. Ongoing research is also investigating numerous antibodies that modulate myo-
statin and the activin II receptor, as well as ghrelin agonists, which increase food intake and 
release growth hormone [7].
The potential impact of clearly addressing SMFD and properly integrating muscle mass, mus-
cle strength, and muscle quality is critical to future therapeutic development to help older 
adults with muscle dysfunctions maintain independence and quality of life.
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